Three-quarters of treatments in Cancer Drugs Fund given positive recommendations
By Neil Trainis
PUBLISHED: August 11, 2017 | UPDATED: August 11, 2017
The National Institute for Health and Care Excellence has said it has given positive recommendations for three-quarters of treatments in the Cancer Drugs Fund (CDF) for use on the NHS.
Eighteen of 24 treatments NICE was asked to review have been approved in final or draft guidance with one drug, liver cancer drug sorafenib (Nexavar), remaining on the CDF under what NICE described as “special arrangements that will see further data collected whilst it is funded at a discounted price.”
Professor Carole Longson, director of the NICE centre for health technology evaluation, said: “Working closely with companies and NHS England, we are delivering our promise to give people fast access to the most cost-effective cancer drugs.
“More cancer drugs than ever are being recommended for routine use because companies are working hard to provide cost-effective solutions. We are also applying flexibility in cases where drugs show promise, meaning people get access through the new CDF while further data is generated.”